Regeneron Pharmaceuticals

REGN

Biotechnology · Healthcare

Also trades as: 0R2M.L

Exchange

NASDAQ

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Strong

Growth

Mixed

Cash Flow

Exceptional

Stability

Exceptional

Valuation

Strong

Dividends

Weak

Track this stock — start free trial

Winston Score History

The full picture

Regeneron Pharmaceuticals is a US biotechnology company that discovers and develops medicines to treat serious diseases. Its biggest product is Dupixent, a drug that treats conditions like eczema, asthma, and nasal polyps, which it sells in partnership with Sanofi. Regeneron also makes Eylea, a widely used treatment for eye diseases like macular degeneration, and has a growing portfolio of cancer and rare disease drugs.

Regeneron makes money by selling its medicines to hospitals, pharmacies, and specialty distributors, primarily in the United States and Europe. The company generates over $13 billion in annual revenue and has a strong competitive position because developing new biologics is expensive and time-consuming, making it hard for rivals to copy its drugs quickly. Dupixent continues to expand into new disease areas, which is the main growth driver, but Eylea faces increasing competition from biosimilars, which could pressure that part of the business.

Politician Trades

20 trades / 12mo

13 Congressional buys and 7 sells on REGN in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+16.7% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-4.9% YoY

YoY Growth Rate

Earnings declining

Insider Activity

2.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$8.0B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Regeneron Pharmaceuticals is a rare growth stock that's already generating positive cash flow while growing at 17%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

86.6%

Premium pricing power — 86.6% gross margin

Profit after running costs

Operating Margin

30.1%

Excellent — 30.1% operating margin

Return on the money invested

ROCE

9.3%

Below par — 9.3% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+9.3%

Steady sales growth (+9.3% YoY)

Profit growth

EPS YoY

+0.3%

Flat earnings

Single-digit earnings growth — steady but not exciting.

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

108%

Turns 108% of profit into real cash

Spare cash per sale

FCF Margin

24.2%

Converts sales into free cash efficiently (24.2%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.07

Conservative — low debt load (0.07)

Covers its interest

Interest Cover

69.37x

Comfortably covers interest (69.4x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

19.9x

no trend

Fair value — P/E 19.9

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year

P/E vs Forward

+8.4

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (19.9 → 11.6)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

0.48%

no trend

Small dividend — 0.48% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial